Literature DB >> 33622868

Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.

Akinori Minato1, Hirotsugu Noguchi2, Rei Ohnishi3, Ikko Tomisaki3, Toshiyuki Nakayama4, Naohiro Fujimoto3.   

Abstract

BACKGROUND/AIM: The role of glutathione peroxidase 2 (GPX2) expression in urothelial carcinoma (UC) is rarely reported. The aim of this study was to assess the expression status of GPX2 in UC of the bladder.
MATERIALS AND METHODS: We collected samples from 112 patients treated with radical cystectomy for immunohistochemical study.
RESULTS: Following immunohistochemical analysis of the specimens, 86 (76.8%) had weak GPX2 expression. In cases with consistent GPX2 expression within the same lesion, the levels of GPX2 showed significant decreases from pTa to pT1 (47.1%) compared to those from pT1 to pT2 (5.9%) (p=0.017). Specimens obtained with transurethral resection before cancer progressed to muscle invasive bladder cancer showed that pT1 had a lower expression for GPX2 than that of pTa (63.3% vs. 93.3%; p=0.009).
CONCLUSION: The decrease in GPX2 expression among those with UC of the bladder may be involved in the early step of cancer invasion. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Urothelial carcinoma; bladder cancer; glutathione peroxidase 2 (GPX2); immunohistochemistry; invasion

Mesh:

Substances:

Year:  2021        PMID: 33622868      PMCID: PMC8045116          DOI: 10.21873/invivo.12316

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  24 in total

1.  Pathology and Genetics: Tumours of the Urinary System and Male Genital System: Clinical Implications of the 4th Edition of the WHO Classification and Beyond.

Authors:  Rodolfo Montironi; Liang Cheng; Marina Scarpelli; Antonio Lopez-Beltran
Journal:  Eur Urol       Date:  2016-03-17       Impact factor: 20.096

2.  The relationship between antioxidant enzymes and bladder cancer.

Authors:  S Arikan; T Akcay; D Konukoglu; C Obek; A R Kural
Journal:  Neoplasma       Date:  2005       Impact factor: 2.575

3.  Clinicopathological and prognostic significance of GPx2 protein expression in nasopharyngeal carcinoma.

Authors:  C Liu; X He; X Wu; Z Wang; W Zuo; G Hu
Journal:  Cancer Biomark       Date:  2017-07-04       Impact factor: 4.388

Review 4.  Glutathione peroxidases.

Authors:  Regina Brigelius-Flohé; Matilde Maiorino
Journal:  Biochim Biophys Acta       Date:  2012-11-29

5.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

6.  Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens.

Authors:  Aya Naiki-Ito; Makoto Asamoto; Naomi Hokaiwado; Satoru Takahashi; Hiroko Yamashita; Hiroyuki Tsuda; Kumiko Ogawa; Tomoyuki Shirai
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

7.  Aberrant expression of selenoproteins in the progression of colorectal cancer.

Authors:  Yoshiyuki Murawaki; Hiroyuki Tsuchiya; Takamasa Kanbe; Kenichi Harada; Kazuo Yashima; Kimiyasu Nozaka; Osamu Tanida; Michimori Kohno; Tomoyuki Mukoyama; Eiji Nishimuki; Haruhiko Kojo; Tatsuya Matsura; Kazuhiko Takahashi; Mitsuhiko Osaki; Hisao Ito; Junji Yodoi; Yoshikazu Murawaki; Goshi Shiota
Journal:  Cancer Lett       Date:  2007-12-03       Impact factor: 8.679

8.  Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladder cancer: potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer.

Authors:  Yongzhang Liu; Linhua Lan; Kate Huang; Rongrong Wang; Cuicui Xu; Yang Shi; Xiaoyi Wu; Zhi Wu; Jiliang Zhang; Lin Chen; Lu Wang; Xiaomin Yu; Haibo Zhu; Bin Lu
Journal:  Oncotarget       Date:  2014-11-30

9.  GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis.

Authors:  Taku Naiki; Aya Naiki-Ito; Keitaro Iida; Toshiki Etani; Hiroyuki Kato; Shugo Suzuki; Yoriko Yamashita; Noriyasu Kawai; Takahiro Yasui; Satoru Takahashi
Journal:  Oncotarget       Date:  2018-03-23

10.  Clinicopathological and prognostic significance of GPX2 protein expression in esophageal squamous cell carcinoma.

Authors:  Zhijin Lei; Dongping Tian; Chong Zhang; Shukun Zhao; Min Su
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.